真人养脏汤核心成分治疗溃疡性结肠炎的网络药理学研究
Network Pharmacology Study on the Key Components of Zhenren Yangzang Decoction in the Treatment of Ulcerative Colitis
DOI: 10.12677/tcm.2025.143181, PDF,    科研立项经费支持
作者: 叶梦琪*#:南昌医学院临床医学院,江西 南昌;王 飞:江西中医药大学附属医院,江西 南昌
关键词: 溃疡性结肠炎真人养脏汤网络药理学Ulcerative Colitis ZRYZ Network Pharmacology
摘要: 目的:采用网络药理学方法研究真人养脏汤治疗溃疡性结肠炎(UC)的作用机制。方法:在相关数据库中筛选真人养脏汤的有效成分和潜在靶点,构建化合物–靶点网络。然后筛选UC的靶点,所得出共同的靶点,形成PPI网络用于预测核心的靶点。并对所得到的结果进行GO和KEGG富集分析。结果:共预测了6种有效成分和77个共同靶点。山萘酚,B-谷甾醇,玫瑰树碱,鞣花酸,豆固醇,异癸酸为药物关键有效活性成分,作用机制可能与癌症信号通路、脂质与动脉粥样硬化通路、化学致癌–受体激活通路、乙肝通路、人类疱疹病毒第四型感染通路、人类免疫缺陷病毒感染通路等信号通路有关。HSP90AA1、MAPK8、TNF、CASP3是UC治疗的关键靶点。结论。本研究体现了ZRYZ多成分、多靶点、多通路治疗溃疡性结肠炎的复杂网络关系,为治疗UC提供了思路。
Abstract: Objective: To study the mechanism of action of ZRYZ for the treatment of ulcerative colitis (UC) using a network pharmacology approach. Methods: We screened the active ingredients and potential targets of ZRYZ in relevant databases, and constructed a compound-target network. Then the targets of UC were screened, and the resulting common targets were used to construct a PPI network to further identify the core targets. And the results were analyzed by GO and KEGG enrichment. Results: A total of 6 active ingredients and 77 common targets were predicted. Sennosol, B-sitosterol, rosmarinic acid, ellagic acid, stigmasterol, and isodecanoic acid were the key active ingredients of the drug, and the mechanism of action might be related to the signaling pathways of cancer signaling pathway, lipid and atherosclerosis pathway, chemo oncogenic-receptor-activated pathway, hepatitis B pathway, human herpesvirus type IV infection pathway, and human immunodeficiency virus infection pathway, etc. HSP90AA1, MAPK8, TNF, and CASP3 are key targets for UC therapy. Conclusion. This study exemplifies the complex network relationship of ZRYZ multi-component, multi-target, and multi-pathway for the treatment of ulcerative colitis, which provides ideas for the treatment of UC.
文章引用:叶梦琪, 王飞. 真人养脏汤核心成分治疗溃疡性结肠炎的网络药理学研究[J]. 中医学, 2025, 14(3): 1212-1219. https://doi.org/10.12677/tcm.2025.143181

参考文献

[1] Burri, E., Maillard, M.H., Schoepfer, A.M., Seibold, F., Van Assche, G., Rivière, P., et al. (2020) Treatment Algorithm for Mild and Moderate-To-Severe Ulcerative Colitis: An Update. Digestion, 101, 2-15. [Google Scholar] [CrossRef] [PubMed]
[2] Shen, Z., Zhu, C., Quan, Y., Yang, Z., Wu, S., Luo, W., et al. (2018) Relationship between Intestinal Microbiota and Ulcerative Colitis: Mechanisms and Clinical Application of Probiotics and Fecal Microbiota Transplantation. World Journal of Gastroenterology, 24, 5-14. [Google Scholar] [CrossRef] [PubMed]
[3] Yashiro, M. (2014) Ulcerative Colitis-Associated Colorectal Cancer. World Journal of Gastroenterology, 20, 16389-16397. [Google Scholar] [CrossRef] [PubMed]
[4] Du, L. and Ha, C. (2020) Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterology Clinics of North America, 49, 643-654. [Google Scholar] [CrossRef] [PubMed]
[5] 孙亦华, 李戟玭, 张文凯, 等. 炎症性肠病共病的研究进展[J]. 现代消化及介入诊疗, 2022, 27(8): 1042-1049.
[6] Guo, M. and Wang, X. (2023) Pathological Mechanism and Targeted Drugs of Ulcerative Colitis: A Review. Medicine, 102, e35020. [Google Scholar] [CrossRef] [PubMed]
[7] Gros, B. and Kaplan, G.G. (2023) Ulcerative Colitis in Adults. JAMA, 330, 951-965. [Google Scholar] [CrossRef] [PubMed]
[8] Loftus, E.V., Feagan, B.G., Panaccione, R., Colombel, J., Sandborn, W.J., Sands, B.E., et al. (2020) Long‐Term Safety of Vedolizumab for Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 52, 1353-1365. [Google Scholar] [CrossRef] [PubMed]
[9] Al-abcha, A., Raziq, F., Kherallah, S. and Alratroot, A. (2020) Mesalamine-Induced Eosinophilic Pleural Effusion. BMJ Case Reports, 13, e233886. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, M., Fu, R., Xu, D., Chen, Y., Yue, S., Zhang, S., et al. (2024) Traditional Chinese Medicine: A Promising Strategy to Regulate the Imbalance of Bacterial Flora, Impaired Intestinal Barrier and Immune Function Attributed to Ulcerative Colitis through Intestinal Microecology. Journal of Ethnopharmacology, 318, Article ID: 116879. [Google Scholar] [CrossRef] [PubMed]
[11] 王慧, 毛晶磊, 吴艳敏, 王琪, 罗晓庆, 官杰. 真人养脏汤对溃疡性结肠炎大鼠肠道黏膜屏障功能的保护作用[J]. 中国病理生理杂志, 2017, 33(11): 2053-2059.
[12] 何青华. 真人养脏汤合暖肝煎加减治疗溃疡性结肠炎(脾肾阳虚证)的临床研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2020.
[13] 秦婧芬. 二真汤治疗溃疡性结肠炎(脾肾阳虚证)的临床研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2018.
[14] 王璐, 刘冬梅. 真人养脏汤合四逆汤治疗脾肾阳虚型溃疡性结肠炎40例总结[J]. 湖南中医杂志, 2015, 31(10): 43-44.